周永飞;杨敬鹏;常军亮;曹玉锋;

• 1:长春生物制品研究所有限责任公司
• 2:国家药品监督管理局食品药品查验中心
• 3:怡道生物科技(苏州)有限公司

摘要(Abstract)：

人源化单克隆抗体目前在肿瘤、自身免疫病、抗病毒等多个治疗领域发挥着越来越重要的作用。截止目前,FDA已有50多种人源化抗体药物获批上市,人源化抗体为人类疾病的治疗提供了广阔的思路。抗体人源化技术包括嵌合抗体技术、人源化抗体技术和全人源抗体技术,并随之衍生出单链抗体、双特异性抗体、纳米抗体等多种形式的小分子人源化单克隆抗体。本文对人源化单克隆抗体技术及人源化抗体的发展形势作一综述。

关键词(KeyWords)： 单克隆抗体;全人源抗体;抗体人源化技术

Abstract:

Keywords:

基金项目(Foundation): 吉林省科技发展计划项目（20160204034YY）

作者(Authors): 周永飞;杨敬鹏;常军亮;曹玉锋;

DOI: 10.13200/j.cnki.cjb.003437

参考文献(References)：

• [1]ALMAGRO J C,DANIELS-WELLS T R,PEREZ-TAPIA S M,et al.Progress and challenges in the design and clinical development of antibodies for cancer therapy[J].Frontiers Immunol,2017,8:1751.
• [2]LITZOW M R.Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia[J].Am Soci Clin Oncol,2013:294-299.
• [3]SARNO M A,MANCARI R,AZIM H A,et al.Are monoclonal antibodies a safe treatment for cancer during pregnancy[J].Immunotherapy,2013,5(7):733-741.
• [4]LANARI M,VANDINI S,ARCURI S,et al.The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection[J].Clin&Develop Immunol,2013,2013:359683.
• [5]DAVDA J,DECLERCK P,HU-LIESKOVAN S,et al.Immunogenicity of immunomodulatory,antibody-based,oncology therapeutics[J].J Immunother Cancer,2019,7(1):105.
• [6]GEISS R,DE LA MOTTE ROUGE T,DUBOT C,et al.Targeted therapy in locally and metastatic recurrent cervical cancers[J].Bull Du Cancer,2014,101(7-8):748-755.
• [7]GOROVITS B,KOREN E.Immunogenicity of chimeric antigen receptor T-cell therapeutics[J].Bio Drugs Clin Immunother Biopharm Gene Ther,2019,33(3):275-284.
• [8]HASHIMOTO Y,TADA M,IIDA M,et al.Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model[J].Biochem Biophys Res Communi,2016,477(1):91-95.
• [9]PIERPONT T M,LIMPER C B,RICHARDS K L.Past,present,and future of Rituximab-The world's first oncology monoclonal antibody therapy[J].Frontiers Oncol,2018,8:163.
• [10]HYYTIH,HEIKKILT,BROCKMANN E C,et al.Chimeric recombinant antibody fragments in cardiac troponin I immunoassay[J].Clin Biochem,2015,48(4-5):347-352.
• [11]WOLLINA U,TCHERNEV G,LOTTI T.Chimeric monoclonal antibody Cetuximab targeting epidermal growth factor-receptor in advanced non-melanoma skin cancer[J].Open Access Macedonian J Med Sci,2018,6(1):152-155.
• [12]GUO H,CHEN H,ZHU Q,et al.A humanized monoclonal antibody targeting secreted anterior gradient 2 effectively inhibits the xenograft tumor growth[J].Biochem Biophys Res Communi,2016,475(1):57-63.
• [13]ROH J,BYUN S J,SEO Y,et al.Generation of a chickenized catalytic anti-nucleic acid antibody by complementarity-determining region grafting[J].Mol Immunol,2015,63 (2):513-520.
• [14]KIM J H,HONG H J.Humanization by CDR grafting and specificity-determining residue grafting[J].Mtd Mol Biol(Clifton,NJ),2012,907:237-245.
• [15]NORN C H,LAPIDOTH G,FLEISHMAN S J.High-accuracy modeling of antibody structures by a search for minimum-energy recombination of backbone fragments[J].Proteins,2017,85(1):30-38.
• [16]ALMAGRO J C,FRANSSON J.Humanization of antibodies[J].Frontiers Biosci,2008,13:1619-1633.
• [17]SAFDARI Y,FARAJNIA S,ASGHARZADEH M,et al.Antibody humanization methods-a review and update[J].Biotechnol&Genetic Engi Rev,2013,29:175-186.
• [18]TOMSZAK F,WEBER S,ZANTOW J,et al.Selection of recombinant human antibodie[J].Adv Exp Med Biol,2016,917:23-54.
• [19]KAMIMURA N,WOLF A M,IWAI Y.Development of cancer immunotherapy targeting the PD-1 pathway[J].J Nippon Med School,2019,86(1):10-14.
• [20]BRGGEMANN M,OSBORN M J,MA B,et al.Human antibody production in transgenic animals[J].Arch Immunol et Ther Exp,2015,63(2):101-108.
• [21]GREEN L L.Transgenic mouse strains as platforms for the successful discovery and development of human therapeutic monoclonal antibodies[J].Current Drug Discov Technol,2014,11(1):74-84.
• [22]AKKAPEDDI P,FRAGOSO R,HIXON J A,et al.A fully human anti-IL-7Rantibody promotes antitumor activity against T-cell acute lymphoblastic leukemia[J].Leukemia,2019.doi:10.1038/s41375-019-0434-8.
• [23]ITOH K,REIS A H,HAYHURST A,et al.Isolation of nanobodies against Xenopus embryonic antigens using immune and non-immune phage display libraries[J].Plo S One,2019,14(5):e0216083.doi:10.1371/journal.pone.0216083.e Collection 2019.
• [24]CHAN C E,LIM A P,MACARY P A,et al.The role of phage display in therapeutic antibody discovery[J].Int Immunol,2014,26(12):649-657.
• [25]ZOU Y,XU W,LI J.Chimeric antigen receptor-modified Tcell therapy in chronic lymphocytic leukemia[J].J Hematol&Oncol,2018,11(1):130.
• [26]LIM C C,WOO P C Y,LIM T S.Development of a phage display panning strategy utilizing crude antigens:Isolation of MERS-Co V nucleoprotein human antibodies[J].Sci Rep,2019,9(1):6088.
• [27]JAFARI B,HAMZEH-MIVEHROUD M,MORRIS M B,et al.Exploitation of phage display for the development of anti-cancer agents targeting fibroblast growth factor signaling pathways:New strategies to tackle an old challenge[J].Cytokine&Growth Factor Rev,2019,46:54-65.
• [28]MAINI R,UMEMOTO S,SUGA H.Ribosome-mediated synthesis of natural product-like peptides via cell-free translation[J].Curr Opin Chem Biol,2016,34:44-52.
• [29]JOSEPHSON K,RICARDO A,SZOSTAK J W.m RNA display:from basic principles to macrocycle drug discovery[J].Drug Discov Today,2014,19(4):388-399.
• [30]卢晓，凌志洋，孙兵.单克隆抗体制备技术研究进展[J].国际生物制品学杂志，2018,41(5):220.
• [31]DUGEL P U,KOH A,OGURA Y,et al.HAWK and HARRIER:Phase 3,multicenter,randomized,double-masked trials of Brolucizumab for neovascular age-related macular degeneration[J].Ophthalmology,2019.doi:10.1016/j.ophtha.2019.04.017.
• [32]EGAN P C,REAGAN J L.The return of gemtuzumab ozogamicin:a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia[J].Onco Targets Ther,2018,11:8265-8272.
• [33]PONDN,AFTIMOS P,PICCART M.Antibody-drug conjugates in breast cancer:a comprehensive review[J].Curr Treat Options Oncol,2019,20(5):37.
• [34]DONG W,SHI J,YUAN T,et al.Antibody-drug conjugates of7-ethyl-10-hydroxycamptothecin:Sacituzumab govitecan and labetuzumab govitecan[J].Eu J Med Chem,2019,167:583-593.
• [35]FRIGERIO B,BENIGNI F,LUISON E,et al.Effect of radiochemical modification on biodistribution of sc Fv D2B antibody fragment recognising prostate specific membrane antigen[J].Immunol Lett,2015,168(1):105-110.
• [36]VOSTAKOLAEI M A,MOLAVI O,HEJAZI M S,et al.Isolation and characterization of a novel sc Fv antibody fragm-ents specific for Hsp70 as a tumor biomarker[J].J Cell Bio-chem,2019.doi:10.1002/jcb.28732.
• [37]LIU D,ZHAO J,SONG Y,et al.Clinical trial update on bispecific antibodies,antibody-drug conjugates,and antibodycontaining regimens for acute lymphoblastic leukemia[J].JHematol&Oncol,2019,12(1):15.
• [38]IGAWA T.Next generation antibody therapeutics using bispecific antibody technology[J].Yakugaku zasshi,2017,137(7):831-836.
• [39]VANDGHANOONI S,ESKANDANI M,BARAR J,et al.Bispecific therapeutic aptamers for targeted therapy of cancer:a review on cellular perspective[J].J Mol Med,2018,96(9):885-902.
• [40]YU L,WANG J.T cell-redirecting bispecific antibodies in cancer immunotherapy:recent advances[J].J Cancer Res Clin Oncol,2019,145(4):941-956.
• [41]LUTHRA A,LANGLEY D B,SCHOFIELD P,et al.Human antibody bispecifics through phage display selection[J].Biochemistry,2019,58(13):1701-1704.
• [42]VIARDOT A,BARGOU R.Bispecific antibodies in haematological malignancies[J].Cancer Treat Rev,2018,65:87-95.
• [43]ESQUIVEL R N,PATEL A,KUDCHODKAR S B,et al.In vivo delivery of a DNA-encoded monoclonal antibody protects non-human primates against Zika virus[J].Mol Ther,2019,27(5):974-985.
• [44]TORRES L A,PERERA A,BATISTA J F,et al.Phase I/IIclinical trial of the humanizedanti-EGF-r monoclonal antibody h-R3 labelled with 99m Tc in patients with tumour of epithelial origin[J].Nuclear Med Communi,2005,26(12):1049-1057.